GSK plc
GLAXF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.45 | -0.18 | 0.02 | -3.04 |
| FCF Yield | 6.51% | 7.42% | 8.84% | 7.75% |
| EV / EBITDA | 10.22 | 8.23 | 8.78 | 13.06 |
| Quality | ||||
| ROIC | 8.51% | 14.49% | 13.62% | 9.56% |
| Gross Margin | 71.16% | 71.76% | 67.42% | 65.99% |
| Cash Conversion Ratio | 2.22 | 1.28 | 1.50 | 1.56 |
| Growth | ||||
| Revenue 3-Year CAGR | 2.28% | -3.85% | -4.90% | 0.35% |
| Free Cash Flow Growth | -19.26% | -14.01% | 2.47% | -19.04% |
| Safety | ||||
| Net Debt / EBITDA | 1.99 | 1.66 | 2.01 | 3.07 |
| Interest Coverage | 6.28 | 8.70 | 7.32 | 7.91 |
| Efficiency | ||||
| Inventory Turnover | 1.60 | 1.56 | 1.86 | 2.01 |
| Cash Conversion Cycle | 158.82 | 73.61 | 137.46 | 125.19 |